Citius Pharmaceuticals Secures $6 Million to Fuel Growth
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) has successfully closed its previously announced registered direct offering. This offering raised approximately $6.0 million, allowing the company to accelerate its strategic initiatives in critical care. The company is widely recognized for its dedication to developing and commercializing cutting-edge medical products, particularly in the field of biopharmaceuticals.
Details of the Direct Offering
The direct offering involved the purchase of 3,973,510 shares of the company’s common stock, or pre-funded warrants, at a purchase price of $1.51 per share. Along with the shares, investors received accompanying common warrants that allow them to purchase up to an aggregate of the same number of common stock shares at an exercise price of $1.40 per share. These common warrants are exercisable immediately upon issuance and will remain valid for five years. This structure positions the company to maximize its fundraising potential while providing flexibility for investors.
Utilization of Funds
The net proceeds from this offering are intended to support the upcoming launch of LYMPHIR™, an innovative immunotherapy recently approved by regulatory authorities. Funds will also contribute toward milestone payments, regulatory fees, and various developmental initiatives across Citius Pharma's product pipeline. This multi-faceted approach ensures that the company is well-equipped to tackle the challenges of bringing new therapies to market.
Company’s Focus and Pipeline
Citius Pharmaceuticals is focused on creating first-in-class critical care technologies. Their notable pipeline includes LYMPHIR™, specifically designed to address cutaneous T-cell lymphoma, as well as Mino-Lok, which targets catheter-related bloodstream infections, and CITI-002 (Halo-Lido), an innovative solution for hemorrhoids. Plans are currently underway for pivotal clinical trials involving these products, demonstrating a robust commitment to research and development.
About Citius Pharmaceuticals
Citius Pharmaceuticals stands at the forefront of biopharmaceutical innovation. As a dedicated enterprise in the development of new therapies, their recent achievements, including FDA approval for LYMPHIR™, situate them as a leading player in the industry. Their substantial involvement in clinical trials not only targets immediate patient needs but also advances the entire sector.
Investor Relations and Contacts
For investor relations inquiries, stakeholders can reach out to Ilanit Allen at Citius Pharmaceuticals to discuss opportunities or seek information about upcoming products and initiatives. Contact details are available through official company communications, ensuring that inquiries are handled promptly and efficiently. Media representatives can connect with Greg Salsburg for information regarding press-related requirements.
Frequently Asked Questions
What is Citius Pharmaceuticals known for?
Citius Pharmaceuticals is known for developing innovative therapies in critical care, focusing on diseases like cutaneous T-cell lymphoma.
How much money did Citius Pharmaceuticals raise?
The company raised approximately $6.0 million through a registered direct offering.
What will the funds from the offering be used for?
The funds will support the launch of LYMPHIR™, regulatory expenses, and development initiatives for the company's product pipeline.
What products are in Citius Pharmaceuticals' pipeline?
Their pipeline includes LYMPHIR™, Mino-Lok, and CITI-002 (Halo-Lido), each targeting significant medical needs in critical care.
Who can I contact for investor relations inquiries?
Investors can contact Ilanit Allen for inquiries regarding company activities and investment opportunities.
